Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 73-75

  Masui, Takuya ^a   Kusumi, Ichiro ^a   Takahashi, Yoshito ^b   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sapporo General Hospital   (Japan)

Author keywords

Atypical antipsychotics; Healthy subject; Itraconazole; Perospirone; Pharmacokinetics

Indexed keywords

CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A4; ID 15036; ITRACONAZOLE; N [4 [4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYL]BUTYL] 1 HYDROXY 1 , 2 CYCLOHEXANEDICARBOXIMIDE; NEUROLEPTIC AGENT; PEROSPIRONE; TANDOSPIRONE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CYP3A4 PROTEIN, HUMAN; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SEROTONIN AGONIST; THIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; HUMAN; MALE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG INTERACTION; HALF LIFE TIME; METABOLISM; MIDDLE AGED;

ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HALF-LIFE; HUMANS; INDOLES; ITRACONAZOLE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SEROTONIN AGONISTS; THIAZOLES;

EID: 33745480691     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000185767.59749.bb     Document Type: Article

References (10)

1. Kato T, Hirose A, Ohno Y, et al. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol. 1990;54:478-481.
2. Mizuno Y, Tani N, Komuro S, et al. In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet. 2003;28:59-66.
3. 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm. 1998;105:181-191.
4. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(Suppl 2):37-44.
5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the anti-fungal agents on oxidative drug metabolism. Clin Pharmacokinet. 2000;38:111-180.
6. Mizuno Y, Tani N, Kanamaru H, et al. In vitro metabolism of tandospirone. Drug Metab Pharmacokinet. 1997;12S:251.
7. Nakashima M, Kanemaru M. Phase I study of new non-benzodiazepine antianxiety drug, SM-3997. Kiso to Rinsh. 1992;26:4143-4165.
8. Yasui-Furukori N, Inoue Y, Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B. 2003;789:239-245.
9. Yasui-Furukori N, Furukori H, Nakagami T, et al. Steady-state pharmacokinetics of a newantipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004;26:361-365.
10. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159:133-135.